Canaccord raises Verona Pharma target to $72; maintains buy
Canaccord Genuity maintained a Buy rating on Verona Pharma (NASDAQ:VRNA) while significantly increasing the price target to $72.00 from the previous $44.00. According to InvestingPro data, analyst ...
DoorDash (DASH) Gets a Hold from Roth MKM
In a report released today, Rohit Kulkarni from Roth MKM maintained a Hold rating on DoorDash (DASH – Research Report), with a price target of ...